argenxARGX
Market Cap: $32.4B
About: Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Employees: 1,148
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
24% more repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 104
16% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 44
8% more capital invested
Capital invested by funds: $13.6B [Q1] → $14.7B (+$1.09B) [Q2]
2% more funds holding
Funds holding: 321 [Q1] → 328 (+7) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 20 [Q1] → 20 (+0) [Q2]
0.79% less ownership
Funds ownership: 58.41% [Q1] → 57.62% (-0.79%) [Q2]
35% less call options, than puts
Call options by funds: $134M | Put options by funds: $206M
Research analyst outlook
24 Wall Street Analysts provided 1 year price targets over the past 3 months
24 analyst ratings
JP Morgan James Gordon 100% 1-year accuracy 3 / 3 met price target | 18%upside $640 | Overweight Maintained | 23 Aug 2024 |
Baird Joel Beatty 51% 1-year accuracy 18 / 35 met price target | 5%downside $515 | Outperform Maintained | 29 Jul 2024 |
Guggenheim Yatin Suneja 65% 1-year accuracy 13 / 20 met price target | 8%upside $585 | Buy Maintained | 26 Jul 2024 |
Oppenheimer Leland Gershell 55% 1-year accuracy 27 / 49 met price target | 3%upside $560 | Outperform Maintained | 26 Jul 2024 |
Wedbush David Nierengarten 54% 1-year accuracy 33 / 61 met price target | 3%upside $560 | Outperform Maintained | 26 Jul 2024 |
Financial journalist opinion
Based on 5 articles about ARGX published over the past 30 days